Contineum Therapeutics (CTNM)
Discovers and develops oral small-molecule therapies for neuroscience, inflammation and immunology.
$12.81
vs last close−0.59 (−4.41%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 81.76% | 30.76M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.44% | 166.0K shares | |
| 3 holders · as of Sep 8, 2026 | |||
| Strategic holders | 6.51% | 2.45M shares | |
| 1 holder · as of Feb 17, 2026 | |||
| Other | ≈ 11.29% | 4.25M shares | |
| remainder | |||
37.62M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
105 holders · 30.76M shares · 31 new positions · 63 increased · 19 reduced · 17 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2.84M | 7.55% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 2.73M | 7.27% | +2.73Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 2.06M | 5.49% | +1.40M | Aug 7, 2026 |
| Johnson & Johnson | 1.98M | 5.26% | 0 | Aug 6, 2026 |
| Franklin Resources Inc | 1.84M | 4.89% | 0 | Aug 13, 2026 |
| Balyasny Asset Management L.P. | 1.52M | 4.05% | −162.8K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.32M | 3.51% | +107.2K | Aug 13, 2026 |
| Perceptive Advisors LLC | 1.26M | 3.34% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.90% | 2.45M | 13G | Feb 17, 2026 |
| Balyasny Asset Management L.P. | 7.40% | 2.42M | 13G | May 15, 2026 |
| BlackRock, Inc. | 6.30% | 2.05M | 13G | Jul 27, 2026 |
| Franklin Resources, Inc. | 6.20% | 1.88M | 13G | Jan 29, 2026 |
| Millennium Management LLC | 5.10% | 1.66M | 13G | Apr 17, 2026 |
| Jérôme G. Pfundincl. Sectoral Asset Management Inc. | 5.00% | 950.9K | 13G | Nov 14, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengonedirector, officer: CEO and President | Sale | 2,500 | $16.46 | 17,217 |
| Aug 3, 2026 | Carmine N. Stengonedirector, officer: CEO and President | Sale | 2,500 | $16.01 | 17,217 |
| Jul 9, 2026 | Daniel S. Lorrainofficer: Chief Scientific Officer | Sale | 25 | $16.00 | 135,202 |
| Jul 8, 2026 | Carmine N. Stengonedirector, officer: CEO and President | Sale | 2,500 | $16.00 | 17,217 |
| Jul 1, 2026 | Daniel S. Lorrainofficer: Chief Scientific Officer | Sale · 2 lots | 8,353 | $15.84 | 135,202 |
| Jun 30, 2026 | Daniel S. Lorrainofficer: Chief Scientific Officer | Sale | 28,826 | $16.04 | 139,372 |
| Jun 30, 2026 | Carmine N. Stengonedirector, officer: CEO and President | Sale | 10,000 | $16.01 | 17,217 |
| Jun 30, 2026 | Tim Watkinsofficer: CMO & Head of Development | Sale | 10,833 | $16.02 | 8,961 |
| Jun 1, 2026 | Daniel S. Lorrainofficer: Chief Scientific Officer | Sale | 4,170 | $13.16 | 139,372 |
| May 1, 2026 | Daniel S. Lorrainofficer: Chief Scientific Officer | Sale · 2 lots | 4,170 | $13.12 | 143,542 |
House and Senate disclosures
Not reported.